Aspireo Receives Positive Opinion from EMA for Orphan Disease Designation for Somatoprim

News   Nov 26, 2012

 
Aspireo Receives Positive Opinion from EMA for Orphan Disease Designation for Somatoprim
 
 
 

RELATED ARTICLES

Attacking 'Undruggable' Cancers from the Outside In

News

Many of the most common cancer-causing genes are so central to cellular function throughout the body that they are essentially 'undruggable'. Now, researchers have found a way to attack one of the most common drivers of lung, colorectal, and pancreatic cancer by targeting the proteins it produces on the outside of the cell.

READ MORE

LifeArc and Milner Therapeutics Institute Announce a New Partnership in AI for Target Discovery

News

LifeArc®, the UK-based medical research charity, and the Milner Therapeutics Institute at the University of Cambridge, today announced a new partnership to identify and validate new drug targets in immuno-oncology and respiratory diseases.

READ MORE

Drug-like Compounds Reverse Chemotherapy Failure for 3 Aggressive Cancers

News

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers -- ovarian, prostate and breast.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE